Clinical assessment and management of spasticity: a review

Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand: 2010: 122 (Suppl. 190): 62–66. © 2010 John Wiley & Sons A/S.

[1]  Per Julin,et al.  Short Form 36 assessed health-related quality of life after focal spasticity therapy. , 2009, Journal of rehabilitation medicine.

[2]  M. Latash,et al.  Intrathecal Baclofen for Severe Spinal Spasticity , 1989, The New England journal of medicine.

[3]  James W. Lance,et al.  The control of muscle tone, reflexes, and movement , 1980, Neurology.

[4]  Rainer Koch,et al.  Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study , 2005, Clinical rehabilitation.

[5]  C. Gagnon,et al.  The Use of Botulinum Toxin for Spasticity After Spinal Cord Injury , 2008, American journal of physical medicine & rehabilitation.

[6]  M. Galea,et al.  Measures of muscle and joint performance in the lower limb of children with cerebral palsy , 2003, Developmental medicine and child neurology.

[7]  C. Pozzilli,et al.  Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis , 2007, Clinical rehabilitation.

[8]  Adrienne L Fosang M Physio BAppSc,et al.  Measures of muscle and joint performance in the lower limb of children with cerebral palsy , 2007 .

[9]  B. Ashworth.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. , 1964, The Practitioner.

[10]  B. Mohammadi,et al.  Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients , 2010, Neurological research.

[11]  D. Dressler,et al.  Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence , 2009, Journal of Neural Transmission.

[12]  F. Heinen,et al.  Clinical impact of antibody formation to botulinum toxin A in children , 2004, Annals of neurology.

[13]  F. Biering-Sørensen,et al.  Spasticity-assessment: a review , 2006, Spinal Cord.

[14]  P. Julin,et al.  Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. , 2006, Journal of rehabilitation medicine.

[15]  H. Chambers,et al.  Surgical Management of Spasticity in Persons with Cerebral Palsy , 2009, PM & R : the journal of injury, function, and rehabilitation.

[16]  M. Eyssette,et al.  A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. , 1988, Current medical research and opinion.

[17]  J S Rietman,et al.  Stop using the Ashworth Scale for the assessment of spasticity , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[19]  D. Dressler,et al.  Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity , 2009, Journal of Neural Transmission.

[20]  Allison Brashear,et al.  SPASTICITY , 1996 .

[21]  A. Grossi,et al.  Long‐term intrathecal Baclofen infusion in supraspinal spasticity of adulthood , 2002, Acta neurologica Scandinavica.

[22]  C. Detrembleur,et al.  Effect of Simultaneous Botulinum Toxin Injections Into Several Muscles on Impairment, Activity, Participation, and Quality of Life Among Stroke Patients Presenting With a Stiff Knee Gait , 2008, Stroke.

[23]  Paolo Manganotti,et al.  European consensus table on the use of botulinum toxin type A in adult spasticity. , 2009, Journal of rehabilitation medicine.

[24]  AD Pandyan,et al.  Spasticity, an impairment that is poorly defined and poorly measured , 2009, Clinical rehabilitation.

[25]  S. Hasson,et al.  Inter-rater reliability of the Modified Modified Ashworth Scale in assessing lower limb muscle spasticity , 2009, Brain injury.

[26]  Jean-Michel Gracies,et al.  Pathophysiology of spastic paresis. I: Paresis and soft tissue changes , 2005, Muscle & nerve.

[27]  R. Young.  Spasticity: A review , 1994, Neurology.

[28]  M. Wasay,et al.  Botulinum Toxin Type A with Oral Baclofen Versus Oral Tizanidine: A Nonrandomized Pilot Comparison in Patients with Cerebral Palsy and Spastic Equinus Foot Deformity , 2008, Journal of child neurology.

[29]  A. Ward,et al.  Spasticity treatment with botulinum toxins , 2008, Journal of Neural Transmission.

[30]  A. Frotzler,et al.  Relationship between self- and clinically rated spasticity in spinal cord injury. , 2006, Archives of physical medicine and rehabilitation.

[31]  G. Molenaers,et al.  Safety and efficacy of botulinum toxin type A following long‐term use , 2006, European journal of neurology.

[32]  J. Gracies,et al.  Pathophysiology of spastic paresis. II: Emergence of muscle overactivity , 2005, Muscle & nerve.

[33]  R WARTENBERG,et al.  Pendulousness of the Legs as a Diagnostic Test , 1951, Neurology.

[34]  R. Penn,et al.  Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. , 1993, Journal of neurosurgery.

[35]  J. Kuchta,et al.  Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. , 2007, Acta neurochirurgica. Supplement.

[36]  J. Gracies.  Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. , 2001, Physical medicine and rehabilitation clinics of North America.

[37]  R. Young,et al.  Pathophysiology of spastic paresis , 1990 .

[38]  E. Montané,et al.  Oral antispastic drugs in nonprogressive neurologic diseases , 2004, Neurology.

[39]  L. Kamen,et al.  A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. , 2008, Current medical research and opinion.

[40]  D L Wolfe,et al.  Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility , 2008, Spinal Cord.

[41]  A. Albanese,et al.  Botulinum neurotoxins for post‐stroke spasticity in adults: A systematic review , 2009, Movement disorders : official journal of the Movement Disorder Society.

[42]  M. Médici,et al.  A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. , 1989, Current medical research and opinion.

[43]  I. Milanov,et al.  Mechanisms of tizanidine action on spasticity , 1994, Acta neurologica Scandinavica.

[44]  P. Menei,et al.  Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients , 2004, Spinal Cord.

[45]  G. Francisco.  The role of intrathecal baclofen therapy in the upper motor neuron syndrome. , 2004, Europa medicophysica.

[46]  A. Sherwood,et al.  Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. , 1996, Archives of physical medicine and rehabilitation.

[47]  R. C. Seet,et al.  Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion , 2007, Acta neurologica Scandinavica.